Proto Labs, Inc. — FY2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. This is an annual report, not a standalone fourth-quarter filing; quarterly results are unaudited. Proto Labs provides online, quick-turn CNC machining (Firstcut) and plastic injection molding (Protomold) for prototypes and short-run production.
Financial performance and liquidity
| Metric | FY2012 | FY2011 | Change |
|---|---|---|---|
| Revenue | $126.0 million | $98.9 million | +27.3% |
| Gross profit / margin | $76.1 million / 60.4% | $59.6 million / 60.3% | Margin broadly stable |
| Operating income / margin | $34.9 million / 27.7% | $26.9 million / 27.2% | +30.1% |
| Net income | $24.0 million | $18.0 million | +33.7% |
| Diluted EPS | $0.98 | $0.67 | Comparability affected by IPO and share-count changes |
| Operating cash flow | $25.3 million | $23.5 million | +7.5% |
- FY2012 revenue comprised Protomold $90.4 million, up 22.0%, and Firstcut $35.6 million, up 43.3%. U.S. revenue was $94.9 million, up 29.9%; international revenue was $31.1 million, up 20.0%, or 24.7% of total revenue.
- Fourth-quarter revenue was $33.6 million versus $25.6 million a year earlier; net income was $7.4 million versus $3.2 million. Q4 diluted EPS was $0.29 versus $0.11.
- Cash and cash equivalents were $36.8 million; marketable securities totaled $62.1 million. Working capital was $78.6 million and total assets were $172.7 million at year-end.
- Debt was limited to $0.6 million of capital lease obligations. The $10 million revolving credit facility had no borrowings at year-end and was due to terminate September 30, 2013 unless renewed.
- Capital expenditures were $17.4 million. Investing cash outflow was $79.2 million, largely reflecting purchases of marketable securities; financing cash inflow was $82.8 million, mainly from public offerings.
Changes versus prior period
- Revenue growth slowed to 27.3% in 2012 from 52.4% in 2011. Management attributed 2012 growth primarily to sales and marketing activity and customer additions.
- Gross margin remained essentially flat year over year, as productivity gains were offset by costs of added capacity. Operating margin improved from 27.2% to 27.7%.
- Research and development expense rose 75.0% to $9.1 million, including increased staffing and outside development services. General and administrative expense increased 18.6%, partly due to public-company legal, accounting, and stock-compensation costs.
- Revenue from Firstcut grew faster than Protomold, increasing its share of revenue to 28.3% from 25.1%.
Outlook, commentary, risks, and unusual items
- No numerical revenue or earnings guidance is provided. Management expects continued investment in technology, sales and marketing, personnel, facilities, and manufacturing capacity; it expects operating expenses to rise and anticipates capital expenditures generally around 8%–12% of revenue, excluding potential building purchases.
- Management stated that cash, investments, and operating cash generation should cover working-capital and expenditure needs for at least the next 12 months. It expects to continue developing new offerings: thixomolding of magnesium began operating in Q4 and shipped parts to a small customer group; a steel metal-injection-molding line was installed and sample-part testing began.
- Principal risks include competition and rapid technology change; dependence on customer demand and fast turnaround; scaling facilities, systems, and staffing; concentration of production and computing at a limited number of sites; reliance on some single- or limited-source suppliers; cybersecurity and customer design confidentiality; international, foreign-exchange, and economic risks; and intellectual-property and product-liability claims.
- International operations were not profitable in all markets, according to management, partly because of startup and fixed costs. Foreign-exchange movements reduced 2012 international revenue by approximately $0.3 million.
- The company raised approximately $71.5 million net in its February 2012 IPO and $2.5 million net in a November follow-on offering. It reported no material litigation expected to have a material adverse effect. A 2010 impairment charge of $0.8 million related to Japanese subsidiary assets did not recur; management reported no additional impairment in 2012.
- The auditor issued an unqualified opinion on the financial statements, but did not audit or opine on internal control over financial reporting. Management reported effective disclosure controls; the filing notes that the company was in the newly public company transition period for ICFR reporting.
Important facts for investors to verify
- Whether growth and customer retention can be sustained as growth moderated from 2011; assess new-customer versus existing-customer contributions and regional trends.
- Whether capacity additions and increased R&D spending support growth without pressuring gross or operating margins.
- Progress, commercialization costs, and customer adoption for thixomolding and metal injection molding.
- Liquidity composition and investment maturities, the renewal or replacement of the revolving credit facility, and planned capital expenditures.
- Potential dilution from equity compensation and the effect of the IPO-related increase in shares on per-share comparisons.
- Execution of internal-control reporting requirements and exposure to facility interruptions, supplier constraints, cybersecurity events, and foreign-currency movements.